Single-site baseline and short-term outcomes of clinical characteristics and life quality evaluation of Chinese wet age-related macular degeneration patients in routine clinical practice

Chinese Medical Journal

Volumn 128, Issue 9, 2015, Pages 1154-1159

  Wang, Li Li ^a   Liu, Wen Jia ^a   Liu, Hai Yun ^a   Xu, Xun ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Chinese version of national eye institute visual function questionnaire 25; Ranibizumab; Vision related quality of life; Wet age related macular degeneration

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ASSESSMENT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OBSERVATIONAL STUDY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TREATMENT RESPONSE; VISUAL ACUITY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; PATHOPHYSIOLOGY; QUALITY OF LIFE; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RANIBIZUMAB; WET MACULAR DEGENERATION;

EID: 84929118849     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.156083     Document Type: Article

References (27)

1. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, et al. The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
2. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003;290:2057-60.
3. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
4. Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, Liu K, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 2006;113:373-80.
5. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26.
6. Mackenzie PJ, Chang TS, Scott IU, Linder M, Hay D, Feuer WJ, et al. Assessment of vision-related function in patients with age-related macular degeneration. Ophthalmology 2002;109:720-9.
7. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116:514-20.
8. Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol 2002;133:350-7.
9. Clemons TE, Chew EY, Bressler SB, McBee W, Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No 10. Arch Ophthalmol 2003;121:211-7.
10. Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, et al. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:3354-9.
11. Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007;26:437-51.
12. Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: The Beijing Eye Study. Ophthalmology 2006;113:1134.e1-11.
13. Zou HD, Zhang X, Xu X, Wang FH, Zhang SJ. Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai (in Chinese). Chin J Ophthalmol 2005;41:15-9.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
15. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013;91:540-6.
16. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-8.
17. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000;118:351-8.
18. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119:1388-98.
19. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
20. Yuzawa M, Fujita K, Tanaka E, Wang EC. Assessing quality of life in the treatment of patients with age-related macular degeneration: Clinical research findings and recommendations for clinical practice. Clin Ophthalmol 2013;7:1325-32.
21. Marella M, Pesudovs K, Keeffe JE, O’Connor PM, Rees G, Lamoureux EL. The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci 2010;51:2878-84.
22. Lin JC, Chie WC. Psychometric validation of the Taiwan Chinese version of the 25-Item National Eye Institute Visual Functioning Questionnaire. J Eval Clin Pract 2010;16:619-26.
23. Chan CW, Wong D, Lam CL, McGhee S, Lai WW. Development of a Chinese version of the National Eye Institute Visual Function Questionnaire (CHI-VFQ-25) as a tool to study patients with eye diseases in Hong Kong. Br J Ophthalmol 2009;93:1431-6.
24. Wang CW, Chan CL, Jin HY. Psychometric properties of the Chinese version of the 25-item National Eye Institute Visual Function Questionnaire. Optom Vis Sci 2008;85:1091-9.
25. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511.
26. Globe D, Varma R, Azen SP, Paz S, Yu E, Preston-Martin S, et al. Psychometric performance of the NEI VFQ-25 in visually normal Latinos: The Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2003;44:1470-8
27. Nordmann JP, Viala M, Sullivan K, Arnould B, Berdeaux G. Psychometric Validation of the National Eye Institute Visual Function Questionnaire – 25 (NEI VFQ-25) French version: In a population of patients treated for ocular hypertension and glaucoma. Pharmacoeconomics 2004;22:197-206.